IT1247509B - Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus - Google Patents

Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus

Info

Publication number
IT1247509B
IT1247509B ITMI911096A ITMI911096A IT1247509B IT 1247509 B IT1247509 B IT 1247509B IT MI911096 A ITMI911096 A IT MI911096A IT MI911096 A ITMI911096 A IT MI911096A IT 1247509 B IT1247509 B IT 1247509B
Authority
IT
Italy
Prior art keywords
treatment
rhinovirus infections
synthesis compounds
rhinovirus
infections
Prior art date
Application number
ITMI911096A
Other languages
English (en)
Inventor
Marino Artico
Federico Corelli
Silvio Massa
Antonello Mai
Enzo Tramontano
Alessandra Pani
Maria Elena Marongiu
Colla Paolo La
Original Assignee
Univ Cagliari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cagliari filed Critical Univ Cagliari
Priority to ITMI911096A priority Critical patent/IT1247509B/it
Publication of ITMI911096A0 publication Critical patent/ITMI911096A0/it
Priority to EP92106481A priority patent/EP0509469A1/en
Priority to CA002066394A priority patent/CA2066394A1/en
Priority to US07/870,625 priority patent/US5278184A/en
Priority to KR1019920006514A priority patent/KR920019352A/ko
Priority to JP4128324A priority patent/JPH05148226A/ja
Publication of ITMI911096A1 publication Critical patent/ITMI911096A1/it
Application granted granted Critical
Publication of IT1247509B publication Critical patent/IT1247509B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

La presente invenzione si riferisce a nuovi derivati di composti eterociclici atti all'impiego nella terapia delle infezioni da rhinovirus.
ITMI911096A 1991-04-19 1991-04-19 Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus IT1247509B (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ITMI911096A IT1247509B (it) 1991-04-19 1991-04-19 Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
EP92106481A EP0509469A1 (en) 1991-04-19 1992-04-15 Synthetic compounds suitable for the therapy of infections caused by rhinoviruses
CA002066394A CA2066394A1 (en) 1991-04-19 1992-04-16 Synthetic compounds suitable for the therapy of infections caused by rhinoviruses
US07/870,625 US5278184A (en) 1991-04-19 1992-04-17 Synthetic derivatives of pyrrole and pyrrolidine suitable for the therapy of infections caused by rhinoviruses
KR1019920006514A KR920019352A (ko) 1991-04-19 1992-04-18 리노바이러스(Rhinoviruses)에 의한 감염 치료에 적합한 합성 화합물
JP4128324A JPH05148226A (ja) 1991-04-19 1992-04-20 ライノウイルスによりひき起こされる感染の治療に適した新規な合成化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911096A IT1247509B (it) 1991-04-19 1991-04-19 Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus

Publications (3)

Publication Number Publication Date
ITMI911096A0 ITMI911096A0 (it) 1991-04-19
ITMI911096A1 ITMI911096A1 (it) 1992-10-19
IT1247509B true IT1247509B (it) 1994-12-17

Family

ID=11359712

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI911096A IT1247509B (it) 1991-04-19 1991-04-19 Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus

Country Status (6)

Country Link
US (1) US5278184A (it)
EP (1) EP0509469A1 (it)
JP (1) JPH05148226A (it)
KR (1) KR920019352A (it)
CA (1) CA2066394A1 (it)
IT (1) IT1247509B (it)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1346350A (zh) * 1999-01-22 2002-04-24 依兰制药公司 抑制vla－4介导的白细胞粘着的化合物
EP1144364B1 (en) 1999-01-22 2005-07-13 Elan Pharmaceuticals, Inc. Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
NZ512565A (en) * 1999-01-22 2003-12-19 Elan Pharm Inc Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
US6436904B1 (en) * 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
JP2002538135A (ja) 1999-03-01 2002-11-12 エラン ファーマシューティカルズ，インコーポレイテッド α４β７レセプターアンタゴニストとして有用なα−アミノ酢酸誘導体
US6428942B1 (en) * 1999-10-28 2002-08-06 Fujitsu Limited Multilayer circuit structure build up method
AR034118A1 (es) * 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
CA2462950A1 (en) 2001-10-10 2003-04-17 Sugen, Inc. 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
WO2007041270A1 (en) * 2005-09-29 2007-04-12 Elan Pharmaceuticals, Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
BRPI0616643A2 (pt) * 2005-09-29 2011-06-28 Elan Pharm Inc compostos de carbamato que inibem a adesão leucocitária mediada por vla-4
BRPI0708331A2 (pt) * 2006-02-27 2011-05-24 Elan Pharm Inc compostos de pirimidinil sulfonamida que inibem a adesão leucocitária mediada por vla-4
SG175355A1 (en) * 2009-04-27 2011-12-29 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205078A (en) * 1977-08-03 1980-05-27 Warner-Lambert Company 3-Pyrrolin-2-one derivatives
NZ209209A (en) * 1983-08-29 1988-02-12 Sterling Drug Inc Substituted phenyl-aliphatic isoxazole derivatives and pharmaceutical compositions
US4861791A (en) * 1983-08-29 1989-08-29 Sterling Drug Inc. Dihydro-oxazolyl substituted-phenyl-aliphatic lower alkyl and their use as antiviral agents
ZA846525B (en) * 1983-08-29 1985-04-24 Sterling Drug Inc (substituted)phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof
CA1280753C (en) * 1985-07-02 1991-02-26 Philip Michael Carabateas Process for preparing heterocyclic substituted- phenoxyalkyl isoxazoles and-furans
DE3825559A1 (de) * 1988-07-28 1990-02-01 Basf Ag P-hydroxiphenon-derivate und deren anwendung
GB8912303D0 (en) * 1989-05-27 1989-07-12 Pfizer Ltd Therapeutic agents
US5100893A (en) * 1990-04-18 1992-03-31 Janssen Pharmaceutica N.V. Antipicornaviral pyridazinamines
DE4020851A1 (de) * 1990-06-29 1992-01-02 Cassella Ag 2-(aminoalkyl)-pyrrolaldehyde, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
JPH05148226A (ja) 1993-06-15
US5278184A (en) 1994-01-11
ITMI911096A1 (it) 1992-10-19
CA2066394A1 (en) 1992-10-20
EP0509469A1 (en) 1992-10-21
KR920019352A (ko) 1992-11-19
ITMI911096A0 (it) 1991-04-19

Similar Documents

Publication Publication Date Title
IT1247509B (it) Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
CY1109869T1 (el) Παραγωγη πεπτιδιων και φαρμακευτικα αποδεκτων αλατων τους, τροποι συνθεσης, χρησης και φαρμακευτικης συνθεσης
ATE161836T1 (de) 4-substituierte-2-deoxy-2,3-didehydro alpha-d- neuraminsäure antivirale derivate
IL98382A0 (en) Heterocyclene derivatives
BG101118A (en) Therapeutical compounds
NO933200L (no) Substituerte cykloheksanderivater, fremgangsmåte til fremstilling derav og anvendelsen av forbindelsene til behandling av sykdommer
MX9203417A (es) Compuestos de diarilo antiateroescleroticos.
DE69413118T2 (de) Benzolsulfonamid-Derivate zur Behandlung der Blaseninstabilität
MD1560G2 (ro) Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri
NO940777D0 (no) Anvendelse av et pregnanderivat
IT1151953B (it) Composizione farmaceutica per la cura di affezioni della cavita' orale
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
ES2052670T3 (es) Utilizacion de derivados de 2-pirimidinil-1-piperazina.
GR3022706T3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
ES2147576T3 (es) Utilizacion del efaroxan y de sus derivados para la preparacion de un medicamento destinado al tratamiento de la enfermedad de parkinson.
HUP9801985A3 (en) Use of cystine derivatives for the preparation of pharmaceutical compositions useful for the treatment of restenosis
GT199400041A (es) Derivados de n4 (oxicarbonil substituidos)-5'desoxi-5-fluorocitidina
ITMI911048A0 (it) Nuove composizioni farmaceutiche per il trattamento del morbo di parkinson
ITGE910094A0 (it) Prodotto per la cura e la prevenzione del cancro e dell'aids
IT9019882A0 (it) Composizioni farmaceutiche comprendenti derivati del glicerolo-5- fosfato atte al trattamento di patologie del sistema nervoso
ITMI931201A0 (it) Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
IT9086214A1 (it) Cura o guarigione del cancro o maurosalute
IT1245631B (it) Impiego di composti macrolidi come agenti anti-infiammatori per il trattamento di malattie provocate da cessione di istamina

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960429